Trial
NCT05986422
Methylprednisolone in Patients With Cognitive Deficits in Post-COVID-19 Syndrome (PCS)
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Charite University, Berlin, Germany
Collaborators
—
Condition
Post-COVID-19 Syndrome
Intervention
Methylprednisolone
Why stopped
Following a recommendation from the Data Safety Monitoring Board (DSMB).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-05